Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: A systematic review

Annals of Internal Medicine

Volumn 158, Issue 11, 2013, Pages 807-820

  Chou, Roger ^a   Wasson, Ngoc ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HYALURONIC ACID;

BLOOD EXAMINATION; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT;

EID: 84883419062     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-11-201306040-00005     Document Type: Review

References (216)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14.
2. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol. 2001;8:200-6.
3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-34.
4. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30-4.
5. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-8.
6. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-40.
7. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-95.
8. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26:2S-10S.
9. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-8.
10. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al; HALT-C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:877-83.
11. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
12. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence ofhistological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997;4:199-208.
13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conje- evaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26.
14. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988;95:734-9.
15. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997;92:1302-4.
16. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-13.
17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
18. Omran MM, Farid K, Emran TM, Attallah AA. Fibro-a score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011;12:74-9.
19. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;45:297-306.
20. Calés P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373-81.
21. Attallah AM, Abdallah SO, Attallah AA, Omran MM, Farid K, NasifWA, et al. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Ann Hepatol. 2013;12:44-53.
22. Hsieh YY, Tung SY, Lee IL, Lee K, Shen CH, Wei KL, et al. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J. 2009;32:614-22.
23. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44.
24. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, Makino Y, et al. Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama. 2006;60:77-84.
25. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology. 2004;39:1239-47.
26. Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, et al. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23:701-10.
27. Attallah AM, Omran MM, Farid K, El-Bendary M, Emran TM, Albannan MS, et al. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725-30.
28. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004;41:935-42.
29. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-75.
30. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Marténez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-92.
31. Luo JC, Hwang SJ, Chang FY, Chu CW, Lai CR, Wang YJ, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology. 2002;49:478-81.
32. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus- infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40:867-72.
33. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al; HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47:789-98.
34. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-73.
35. Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King s Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21:730-8.
36. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282-92.
37. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 2004;99:271-9.
38. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96:3142-6.
39. Obrador BD, Prades MG, Gomez MV, Domingo JP, Cueto RB, Rue M, et al. A predictive index for the diagnosis of cirrhosis in hepatitis C based on clinical, laboratory, and ultrasound findings. Eur J Gastroenterol Hepatol. 2006;18:57-62.
40. Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, et al. Non- invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci. 2011;56:555-63.
41. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005;42:1437-45.
42. Chou R, Cottrell E, Wasson N, Rahman B, Guise JM. Screening for Hepatitis C Virus Infection in Adults. Comparative Effectiveness Review no. 69. (Prepared by the Oregon Evidence-based Practice Center under contract 290- 2007-10057-I.) Rockville, MD: Agency for Healthcare Research and Quality; 2012. Accessed at www.effectivehealthcare.ahrq.gov/reports/final.cfm on 26 March 2013.
43. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377-84.
44. Harris RP, Helfend M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J PrevMed. 2001;20:21-35.
45. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-36.
46. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-9.
47. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93.
48. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ. 1994;309:188.
49. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-77.
50. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. Jama. 1994;271:703-7.
51. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329:168-9.
52. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ publication no. 10(12)- EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
53. Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases [Letter]. Hepatology. 2008;47:762-3.
54. Alsatie M, Kwo PY, Gingerich JR, Qi R, Eckert G, Cummings OW, et al. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2007;41:416-21.
55. Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Ferronato Mda G, et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol. 2012;11:855-61.
56. Anderson FH, Zeng L, Rock NR, Yoshida EM. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res. 2000;18:63-71.
57. Arabul M, Aslan F, Alper E, Akpinar Z, Çelik M, Kandemir A, et al. Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients. Turk J Gastroenterol. 2012;23:538-45.
58. Arain SA, Meo SA, Jamal Q. Serum hyaluronic acid level does not reliably differentiate minimal and significant liver disease in chronic hepatitis C. Saudi Med J. 2011;32:1241-5.
59. Attallah AM, Toson El-SA, El-Waseef AM, Abo-Seif MA, Omran MM, Shiha GE. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clin Chim Acta. 2006;369:66- 72.
60. Attallah AM, Shiha GE, Omran MM, Zalata KR. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res. 2006;34:163-9.
61. Attallah AM, Mosa TE, Omran MM, Abo-Zeid MM, El-Dosoky I, Shaker YM. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem. 2007;28:155-68.
62. Attallah AM, Zahran F, Ismail H, Omran MM, El-Dosoky I, Shiha GE. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients with chronic hepatitis C. J Immunoassay Immunochem. 2007;28:331-42.
63. Attallah AM, Abdallah SO, El Sayed AS, Omran MM, El-Bendary M, Farid K, et al. Non-invasive predictive score of fibrosis stages in chronic hepatitis C patients based on epithelial membrane antigen in the blood in combination with routine laboratory markers. Hepatol Res. 2011;41:1075-84.
64. Attallah AM, Badr El-Din NK, Omran MM, Farid K, El-Wahab AH, El-Bendary M, et al. Assessment of matrix metalloproteinase-1 for marking liver cirrhosis in chronic hepatitis C patients. Egypt J Immunol. 2011;18:33-42.
65. Bain VG, Bonacini M, Govindarajan S, Ma M, Sherman M, Gibas A, et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J Viral Hepat. 2004;11:375-82.
66. Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, et al. Validation ofhepascore, compared with simple indices offibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696-701.
67. Bejarano G, Vergara M, Dalmau B, Puig J, Bella MR, Suarez D, et al. Prospective evaluation of liver fibrosis in chronic viral hepatitis C infection using the Sabadell NIHCED (Non-Invasive Hepatitis-C-Related Cirrhosis Early Detection) index. Rev Esp Enferm Dig. 2009;101:325-35.
68. Ben Jazia E, Kaabia N, Benabdelkader A, Khalifa M, Harrabi I, Braham A, et al. Noninvasive fibrosis markers for the prediction of significant fibrosis in patients with chronic hepatitis C virus infection in Tunisia. Infect Dis Clin Pract (Baltim Md). 2009;17:385-7.
69. Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? [Letter]. Hepatology. 2004;39:1456-7.
70. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Licht- inghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. 2002;316:71-81.
71. Borroni G, Ceriani R, Cazzaniga M, Tommasini M, Roncalli M, Maltempo C, et al. Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. Aliment Pharmacol Ther. 2006;24:797-804.
72. Bota S, Sirli R, Sporea I, Focsa M, Popescu A, Danila M, et al. A new scoring system for prediction of fibrosis in chronic hepatitis C. Hepat Mon. 2011;11:548-55.
73. Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-Fridlund D, Tran A, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther. 2008;28:458-67.
74. Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat. 2006;13:659-70.
75. Boursier J, Bacq Y, Halfon P, Leroy V, de Ledinghen V, de Muret A, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21:28-38.
76. Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106:1255-63.
77. Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, et al; multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/ HC/EP23 FIBROSTAR studies. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely nonin- vasive. Hepatology. 2012;55:58-67.
78. Burton MJ, Sunesara I, Penman A, Pham H, Oliver N, Young CA, et al. Comparing the aspartate aminotransferase (AST) to platelet ratio index (APRI) between African American and white veterans with chronic hepatitis C. South MedJ. 2011;104:309-14.
79. Calés P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352-62.
80. Calés P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, et al; multicentric groups (SNIFF 14 & 17, ANRS HC EP 23 Fibrostar). Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem. 2010;43:1315-22.
81. Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-14.
82. Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52:191-8.
83. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment offibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-50.
84. Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, et al; VA HCV-001 Study Group. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol. 2008;42:827-34.
85. Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006;13:652-8.
86. Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol. 2006;18:389-96.
87. Cobbold JF, Crossey MM, Colman P, Goldin RD, Murphy PS, Patel N, et al. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat. 2010;17:537-45.
88. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology. 2005;42:838-45.
89. Colli A, Colucci A, Paggi S, Fraquelli M, Massironi S, Andreoletti M, et al. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol. 2005;11:7318-22.
90. Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. HepatMon. 2012;12:177-84.
91. Cross TJ, Calvaruso V, Maimone S, Carey I, Chang TP, Pleguezuelo M, et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat. 2010;17:546-54.
92. Deghady A, Abdou A, El-Neanaey WA, Diab I. Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C. Genet Test Mol Biomarkers. 2012;16:531-5.
93. Dinesen L, Caspary WF, Chapman RW, Dietrich CF, Sarrazin C, Braden B. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Dig Liver Dis. 2008;40:743-8.
94. Ehsan N, Badr M, Raouf A, Gamal B. Correlation between liver biopsy findings and different serum biochemical tests in staging fibrosis in Egyptian patients with chronic hepatitis C virus infection. Arab J Gastroenterol. 2008;9:7-12.
95. El-Gindy I, El Rahman AT, El-Alim MA, Zaki SS. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol. 2003;10:27-35.
96. El-mezayen HA, Toson el-SA, Shiha GE. Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2013;25:69-76.
97. El-Sayed R, Fahmy M, El Koofy N, El-Raziky M, El-Hawary M, Helmy H, et al. Can aspartate aminotransferase to platelet ratio index replace liver biopsy in chronic hepatitis C? Trop Gastroenterol. 2011;32:267-72.
98. el-Shorbagy E, Afefy AF, Ibrahem IA, Mangoud AM, Eissa MH, Sabee EI, et al. Non-invasive markers and predictors of severity of hepatic fibrosis in HCV patients at Sharkia Governorate, Egypt. J Egypt Soc Parasitol. 2004;34:459-78.
99. Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, et al. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med. 2008;46:253-9.
100. Ferraioli G, Tinelli C, Malfitano A, Dal Bello B, Filice G, Filice C, et al; Liver Fibrosis Study Group. Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosis in chronic hepatitis C. AJR Am J Roentgenol. 2012;199:19-25.
101. Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-Muet M, Nalet B, et al. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C. Gastroenterol Clin Biol. 2008;32:858-65.
102. Fouad SA, Esmat S, Omran D, Rashid L, Kobaisi MH. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol. 2012;18:2988-94.
103. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010;10:103.
104. Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, Dagradi R, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta. 1997;265:21-31.
105. Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11:303-308.e1.
106. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218-24.
107. Giannini E, Testa R. Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple [Letter]. Hepatology. 2003;38:1312-3.
108. Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol. 2006;40:521-7.
109. Silva Jr RG, Fakhouri R, Nascimento TV, Santos IM, Barbosa LM. Aspartate aminotransferase-to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients. Braz J Infect Dis. 2008;12:15-9.
110. Gordon A, Bailey MJ, Gibson PR, Roberts SK. Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:825-32.
111. Grigorescu M, Rusu M, Neculoiu D, Radu C, Serban A, Catanas M, et al. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. J Gastrointestin Liver Dis. 2007;16:31-7.
112. Guéchot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol. 1994;20:388-93.
113. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem. 1996;42:558-63.
114. Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP; ANRS HC EP 23 Fibrostar Study Group. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta. 2010;411:86-91.
115. Guechot J, Trocme C, Renversez JC, Sturm N, Zarski JP; ANRS HC EP 23 Fibrostar Study Group. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med. 2012;50:693-9.
116. Güzelbulut F, Cetinkaya ZA, Sezikli M, Yasar B, Ozkara S, Öviinc AO. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol. 2011;22:279-85.
117. Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta- Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005;4:6.
118. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, et al. Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the Fibropaca study. Am J Gastroenterol. 2006;101:547-55.
119. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:395-402.
120. Halfon P, Penaranda G, Renou C, Bourliere M. External validation of FibroIndex [Letter]. Hepatology. 2007;46:280-1.
121. Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, et al. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol. 2012;18:746-53.
122. Iacobellis A, Fusilli S, Mangia A, Clemente R, Festa V, Giacobbe A, et al. Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther. 2005;22:769-74.
123. Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, et al. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol. 2005;100:868-73.
124. Ichino N, Osakabe K, Nishikawa T, Sugiyama H, Kato M, Kitahara S, et al. A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol. 2010;16:4809-16.
125. Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol. 2000;95:2328-32.
126. Jeffers LJ, Cortes RA, Bejarano PA, Oh E, Regev A, Smith KM, et al. Prospective evaluation of FIBROSpect II for fibrosis detection in hepatitis C and B patients undergoing laparoscopic biopsy. Gastroenterol Hepatol (N Y). 2007; 3:367-76.
127. Kalantari H, Hoseini H, BabakA, Yaran M. Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection. Hepat Res Treat. 2011;2011:972759.
128. Kaul V, Friedenberg FK, Braitman LE, Anis U, Zaeri N, Fazili J, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol. 2002;97:2623-8.
129. Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, et al. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon. 2012;12:e6718.
130. Khan DA, Fatima-Tuz-Zuhra, Khan FA, Mubarak A. Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients. J Ayub Med Coll Abbottabad. 2008;20:122-6.
131. Khokhar N. Serum aminotransferase levels and platelet count as predictive factor of fibrosis and cirrhosis in patients with chronic hepatitis C infection. J Pak Med Assoc. 2003;53:101-4.
132. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376-82.
133. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41:1368-76.
134. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis ofliver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-82.
135. Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, ChenJH, et al. Noninva- sive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int. 2006;26:1087-94.
136. Lo Iacono O, García-Monzón C, Almasio P, García-Buey L, Craxí A, Moreno-Otero R. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Aliment Pharmacol Ther. 1998;12:1091-9.
137. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7:350-7.
138. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212-22.
139. Martinez SM, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138-48.
140. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol. 2000;15:945-51.
141. Metwally MA, Zein CO, Zein NN. Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci. 2007;52:582-8.
142. Morali G, Maor Y, Klar R, Braun M, Ben Ari Z, Bujanover Y, et al. Fibrotest-Actitest: the biochemical marker of liver fibrosis-the Israeli experience. Isr Med Assoc J. 2007;9:588-91.
143. Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;26:847-58.
144. Mossong J, Bill S, Hawotte K, Gilson G, Knolle U, Weber J, et al. Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers. Bull Soc Sci Med Grand Duche Luxemb. 2011:19-30.
145. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol. 2001;36:399-406.
146. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2001;16:777-81.
147. Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poy-nard T; MULTIVIRC Group. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci. 2003;48:146-53.
148. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T; MULTIVIRC Group; Groupe d'Etude Multidisciplinaire sur les Pathologies Liees au Virus C. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97:2419-25.
149. Paggi S, Colli A, Fraquelli M, Vigano M, Del Poggio P, Facciotto C, et al. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. J Hepatol. 2008;49:564-71.
150. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int. 2006;26:1095-9.
151. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. 2000;15:386-90.
152. Park SH, Kim CH, Kim DJ, Suk KT, ParkJH, CheongJY, et al. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C. Clin Biochem. 2011;44:1396-9.
153. Park JJ, ParkJY, Kim do Y, Park YN, Ahn SH, Chon CY, et al. Prediction of significant fibrosis in chronic hepatitis C patients with normal ALT. Hepato- gastroenterology. 2011;58:1321-7.
154. Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18:23-31.
155. Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat. 2009;16:178-86.
156. Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, et al. Serum hyaluronan-a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol. 2000;12:1121-7.
157. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al; GERMED cyt04 group. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9:128-33.
158. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of pegin- terferon alfa-2b and ribavirin. Hepatology. 2003;38:481-92.
159. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36:973-7.
160. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci. 1998;43:2156-9.
161. Renou C, Muller P, Jouve E, Bertrand JJ, Raoult A, Benderriter T, et al. Revelance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus [Letter]. Am J Gastroenterol. 2001;96:1657-9.
162. Romagnuolo J, Jhangri GS, Jewell LD, Bain V.G. Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol. 2001;96:3165-74.
163. Romera M, Corpas R, Romero Gomez M. Insulin resistance as a non- invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. Rev Esp Enferm Dig. 2006;98:161-9.
164. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49:450-4.
165. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196-200.
166. Said Y, Salem M, Mouelhi L, Mekki H, Houissa F, Ben Rejeb M, et al. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C. Tunis Med. 2010;88:573-8.
167. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol. 2005;11:476-81.
168. Schneider AR, Teuber G, Paul K, Nikodem A, Duesterhoeft M, Caspary WF, et al. Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2006;33:300-4.
169. Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1821-7.
170. Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat. 2008;15:212-8.
171. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44:686-93.
172. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011;34:1202-16.
173. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther. 2012;35:92-104.
174. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93:44-8.
175. Shlomai A, Halfon P, Goldiner I, Zelber-Sagi S, Halpern Z, Oren R, et al. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2013;20:95-102.
176. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314-8.
177. Sirli R, Sporea I, Bota S, Popescu A, Cornianu M. A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. Hepat Mon. 2010;10:88-94.
178. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-42.
179. Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY, Lau DT, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta. 2007;381:119-23.
180. Stibbe KJ, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers EJ, et al. Comparison f non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 2011;46:962-72.
181. Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, et al. Nonin- vasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-50.
182. Trocme C, Leroy V, Sturm N, Hilleret MN, Bottari S, Morel F, et al. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat. 2006;13:643-51.
183. Usluer G, Erben N, Aykin N, Dagli O, Aydogdu O, Barut S, et al; Study Group. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2012;31:1873-8.
184. Uyar C, Akcam FZ, Ciris M, Kaya O, Kockar C, Isler M. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroin- flammatory activity in chronic hepatitis B and C. Indian J Pathol Microbiol. 2010;53:470-5.
185. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin- Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-6.
186. Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scand J Gastroenterol. 1997;32:494-9.
187. Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol. 2009;8:26-31.
188. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. Eur J Gastroenterol Hepatol. 1999;11:827-31.
189. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatol. 2000;32:325-30.
190. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metallo- proteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999;44:624-30.
191. Westin J, Ydreborg M, Islam S, Alsioi A, Dhillon AP, Pawlotsky JM, et al; DITTO-HCV Study Group. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol. 2008;43:73-80.
192. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006;43:788-95.
193. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998;5:187-92.
194. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. HepatMon. 2011;11:103-6.
195. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med. 2007;120:280.e9-14.
196. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al; ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56:55-62.
197. Lackner C, Struber G, Bankuti C, Bauer B, Stauber RE. Noninvasive diagnosis of cirrhosis in chronic hepatitis C based on standard laboratory tests [Letter]. Hepatology. 2006;43:378-9.
198. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert- Bismut F, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C [Letter]. Hepatology. 2004;39:862-3.
199. Park G, Jones DB, Katelaris P. Value of AST/ALT ratio as fibrotic predictor in chronic hepatitis C [Letter]. Am J Gastroenterol. 2005;100:1623-4.
200. Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C [Letter]. Hepatology. 2003;37:1220-1.
201. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al; HALT-C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:877-83.
202. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010;139:1230-7.
203. Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based metaanalyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28:138-44.
204. Pham B, Klassen TP, Lawson ML, Moher D. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol. 2005;58:769-76.
205. Schiano TD, Azeem S, Bodian CA, Bodenheimer HC Jr, Merati S, Thung SN, et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2005;3:930-5.
206. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239-44.
207. Obuchowski NA. Estimating and comparing diagnostic tests' accuracy when the gold standard is not binary. Acad Radiol. 2005;12:1198-204.
208. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem. 2008;54:1372-8.
209. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al; FibroPaca Group. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem. 2007;53:1615-22.
210. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102:2589-600.
211. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-21.
212. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36.
213. Poynard T, Ngo Y, Munteanu M, Thabut D, Massard J, Moussalli J, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther. 2010;15:617-31.
214. Andriulli A, Persico M, Iacobellis A, Maio G, Di Salvo D, Spadaccini A, et al. Treatment of patients with HCV infection with or without liver biopsy. J Viral Hepat. 2004;11:536-42.
215. Park JW. [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol. 2005;45:217-26.
216. Castéera L, Le Bail B, Roudot-Thoraval F, Bernard PH, Foucher J, Mer-rouche W, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59-68.